Related Experiment Video
Updated: Dec 15, 2025

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
6-Thioguanine blocks SARS-CoV-2 replication by inhibition of PLpro protease activities
Caleb D Swaim1, Yi-Chieh Perng2, Xu Zhao1
1Department of Molecular Biosciences, University of Texas at Austin, Austin, TX.
Abstract:
A recently emerged betacoronavirus, SARS-CoV-2, has led to a global health crisis that calls for the identification of effective therapeutics for COVID-19 disease. Coronavirus papain-like protease (PLpro) is an attractive drug target as it is essential for viral polyprotein cleavage and for deconjugation of ISG15, an antiviral ubiquitin-like protein. We show here that 6-Thioguanine (6-TG) inhibits SARS-CoV-2 PLpro-catalyzed viral polyprotein cleavage and ISG15 deconjugation in cells and inhibits replication of SARS-CoV-2 in Vero-E6 cells and Calu3 cells at submicromolar levels. As a well-characterized FDA-approved orally delivered drug, 6-TG represents a promising therapeutic for COVID-19 and other emerging coronaviruses.
One Sentence Summary:
A repurposed drug that targets an essential enzymatic activity of SARS-CoV-2 represents a promising COVID-19 therapeutic.
Insights
The drug 6-Thioguanine (6-TG) effectively inhibits SARS-CoV-2 replication by targeting the viral papain-like protease (PLpro). This FDA-approved medication shows promise as an accessible therapeutic for COVID-19 treatment.
Area of Science:
- Virology
- Drug Discovery
- Biochemistry
Background:
- Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes a global health crisis, necessitating novel therapeutics.
- The SARS-CoV-2 papain-like protease (PLpro) is crucial for viral replication and immune modulation, making it a key drug target.
Conclusions:
- 6-Thioguanine is a potent inhibitor of SARS-CoV-2 PLpro enzymatic activity and viral replication.
- As an FDA-approved, orally available drug, 6-TG represents a promising therapeutic candidate for COVID-19 and future coronavirus outbreaks.
Related Concept Videos
RNA Interference
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
Subviral Agents
Viruses with RNA Genomes
Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
siRNA - Small Interfering RNAs
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...

